Maitake-MRL

Maitake-MRL

Maitake
Maitake

Cultivation Process of Maitake MRL

Mycology Research Laboratories Ltd.´s Grifola frondosa, is grown on a sterilised (autoclaved) substrate under ISO 22000:2018 standards in the EU.

This cultivation process ensures the powder complies with the EU regulation 1881/2006 for contamination of pesticides and heavy metals. The cultivation system is proprietary, allowing for standardised production of Grifola frondosa.

MRL mushrooms biomass offers a mixture of many co-operating and co-related healthful bioavailable ingredients prepared by nature itself – it is thus a truly pure natural product.

After cultivation the Grifola frondosa is then manufactured in the Netherlands into 500 mg tablets and in various powder forms to FSSC 22000 (Version 4.1) standards.

Veterinary products are manufactured under veterinary registration number (NL217476).

Moreover, all powder presentations are produced and manufactured in accordance with both EU and UK organic standards.

EU PT Bio 05 Logo
EU NL Bio 01 Logo
EU PT Bio 05 Logo
EU pt Bio 01 Logo
EU PT Bio 05 Logo
APCER 22000 IQNet Logos
UK Organic Logo
UK Organic Logo

Chemical and Biological Properties

Each Tablet of Maitake MRL contains

Grifola frondosa - biomass powder 500 mg

Other ingredients

Microcrystalline Cellulose
Silica
Vegetable Magnesium Sterate

Maitake-MRL - Enzyme Activity Per 750 mg Tablet

Protein content 20.2 mg
Reducing sugars 12.6 mg
Protein-bound polysaccharide 79.5 mg
Peroxidase activity 40.2 mU
Laccase activity 411.5 mU
Glucoamylase / glucansase activity 1.6 U
Protease activity 4.9 U
Superoxide dismutase (SOD) activity 70.2 U
Cytochrome P-450 0.60 nmoles
Cytochrome P-450 reductase 7.14 mU
Secondary metabolites (Thrombin inhibitors) 49%